A detailed history of Core First Bank & Trust transactions in Abb Vie Inc. stock. As of the latest transaction made, Core First Bank & Trust holds 4,052 shares of ABBV stock, worth $717,001. This represents 0.47% of its overall portfolio holdings.

Number of Shares
4,052
Previous 4,082 0.73%
Holding current value
$717,001
Previous $743,000 6.59%
% of portfolio
0.47%
Previous 0.47%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $4,643 - $5,422
-30 Reduced 0.73%
4,052 $694,000
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $10,228 - $11,654
-64 Reduced 1.54%
4,082 $743,000
Q4 2023

Mar 18, 2024

SELL
$137.6 - $154.97 $257,862 - $290,413
-1,874 Reduced 31.13%
4,146 $642,000
Q3 2023

Dec 18, 2023

SELL
$133.59 - $154.65 $2,003 - $2,319
-15 Reduced 0.25%
6,020 $897,000
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $11,925 - $14,841
-90 Reduced 1.47%
6,035 $813,000
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $723 - $832
-5 Reduced 0.08%
6,125 $976,000
Q4 2022

Feb 15, 2023

SELL
$138.31 - $165.87 $2,351 - $2,819
-17 Reduced 0.28%
6,130 $991,000
Q3 2022

Nov 16, 2022

BUY
$134.21 - $153.93 $7,918 - $9,081
59 Added 0.97%
6,147 $825,000
Q2 2022

Aug 16, 2022

SELL
$137.62 - $174.96 $16,514 - $20,995
-120 Reduced 1.93%
6,088 $932,000
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $26,659 - $33,077
202 Added 3.36%
6,208 $1.01 Million
Q4 2021

Feb 10, 2022

SELL
$107.43 - $135.93 $26,857 - $33,982
-250 Reduced 4.0%
6,006 $813,000
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $58,413 - $66,308
-549 Reduced 8.07%
6,256 $675,000
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $547,734 - $739,499
6,805 New
6,805 $729,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Core First Bank & Trust Portfolio

Follow Core First Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core First Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Core First Bank & Trust with notifications on news.